Europe Diabetes Drugs Market – Size, Outlook, Trends and Forecast (2024 – 2032)

Published : 09 February 2026

Report Type : Regional

Share This On

Download Free Sample Now Buy This Report

Home > Reports > Pharmaceuticals > Healthcare > Europe Diabetes Drugs Market – Size, Outlook, Trends and Forecast (2024 – 2032)

Description Table of Contents Scope of the Report

Europe Diabetes Drugs Market - Size

Study Period

2018 - 2032

Base Year For Estimation

2025

Forecast Data Period

2026-2032

Historical Data Period

2018-2024

CAGR

7 %

Source: Envision Intelligence Analysis & Experts Insights.

*Graph shown for illustrative purpose only, the final report will have the graph with actual data and data labels

Doctors often refer diabetes as diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate, or because the body’s cells do not respond appropriately to insulin or both. Patients with high blood sugar typically experience polyuria (frequent urination), and become increasingly thirsty (polydipsia) and hungry (polyphagia).

Europe Diabetes Drugs Market Segments Size & Growth:

Europe diabetes drugs market size is projected to reach approximately $29 billion by the end of 2024 with a CAGR of close to 6.8% from $22 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Rise in some diabetics, Government Initiatives and Complexities in alternative diabetes therapy. However, Cost sensitivity issues, Lack of awareness among people and Regulatory framework issues are thereby hampering the market growth.

Europe Diabetes Drugs Market Segments Share:

Europe diabetes drugs market is categorised into Drugs which comprise of Insulin Derivatives and Oral Diabetic Medication Drugs. By Drugs, Oral Diabetic Medication Drugs segment is expected

Europe Diabetes Drugs Market - Growth

Source: Envision Intelligence Analysis & Experts Insights.

*Graph shown for illustrative purpose only, the final report will have the graph with actual data and data labels

to hold the most significant share in the market. By Geography, UK is projected to dominate the market with the most significant share and the growth in the Europe economies is mainly attributed because of huge profit margins and growth prospects.

Europe Diabetes Drugs Market Trends:

Novo Nordisk is working on Degludec and DegludecPlus as acceptable long-acting choices. It is longer acting and improves blood glucose levels with a lower risk of hypoglycemia, especially during the nighttime. It will be more accessible and more flexible with dosing, possibly three times weekly. Degludec will also have a U-200 version, which allows more insulin in a reduced volume for those who require large amounts. DegludecPlus has a fixed dose of mealtime (30% Novolog) and basal (70% Degludec) insulin. Novo-Nordisk was filing for FDA approval for this new insulin in January 2012.
Echo Therapeutics – The Symphony System. It is a non-needle, non-invasive, wireless trans-dermal continuous glucose monitoring system. The Symphony System uses a biosensor without the need to prick the skin since it

You can also purchase parts of this report. Do you want to check out a section wise price list

Europe Diabetes Drugs Market - Porter's Five Force Analysis

Source: Envision Intelligence Analysis & Experts Insights.

*Graph shown for illustrative purpose only, the final report will have the graph with actual data and data labels

is trans-dermal (it is an adhesive patch placed on the surface). FDA has approved it and is showing substantial successes in clinical trials. Testing is being done on hospitalised critical care patients who require multiple finger sticks daily.

Europe Diabetes Drugs Market Research Report:

An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
Identifying DROC in the current market and their impact in altering the market dynamics.
Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
The primary market players, such as
Novo Nordisk
Eli Lilly and Company
Sanofi Aventis
Medtronic
Novartis

Exclusive Benefits

Credibility and
Transparency

We actively recruit consumers, business professionals, and elusive individuals for our research panels, fostering enduring relationships. Our commitment to transparency is evident in the comprehensive listing of primary and secondary data sources, ensuring unwavering credibility in our reports.

Exhaustive
Coverage

Uncover the full spectrum with Envision Intelligence. Our detailed and extensive geographical coverage, coupled with survey consultation services, spans brand tracking, concept testing, and consumer behaviour analysis. Adapt to your evolving needs with scalable market research services that leave no facet unexplored.

Competitive
Edge

Stay ahead with Envision Intelligence. Our reports provide the latest market updates up to the date of purchase. Recognising the urgency of impactful decisions, we deliver timely analyses on the unprecedented choices made by CXOs during the COVID-19 crisis—providing valuable insights at no extra cost.

Golden
pportunities

Unearth hidden gems with Envision Intelligence. Our analysts and consultants conduct a comprehensive strategic sieve analysis, augmented by AI tools, to identify non-obvious, golden, and emerging opportunities. Evaluate possibilities that set you apart in the market.

Top-notch Reportsd
Guaranteed

Experience unparalleled depth with Envision Intelligence. Over 70% of our research is exclusive, establishing us as the premier source for in-depth and extensive market insights. Elevate your decision-making with reports that go beyond the ordinary.

Post Purchase
Support

Empower your journey with Envision Intelligence. Our commitment extends beyond the purchase. Enjoy post-purchase support for three months, with queries addressed within 24 business hours via telephone or email. We stand by you in your quest for ongoing success.